Oculis Holding AG (OCS)
(Delayed Data from NSDQ)
$11.68 USD
-0.04 (-0.34%)
Updated Jul 22, 2024 02:59 PM ET
After-Market: $11.70 +0.02 (0.17%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OCS 11.68 -0.04(-0.34%)
Will OCS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for OCS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCS
How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77%
What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing'
OCS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect?
Other News for OCS
Oculis and EURETINA Announces the Ramin Tadayoni Award
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Oculis price target lowered by $1 at BofA, here's why
Analysts Are Bullish on These Healthcare Stocks: Oculis Holding (OCS), Akero Therapeutics (AKRO)
Oculis price target raised by $2 at H.C. Wainwright, here's why